ストックスクリーナーアプリを入手
23.32
7.76%
1.68
アフターアワーズ：
23.20
-0.12
-0.51%
前日終値:
$21.64
開ける：
$21.85
24時間の取引高:
548.53K
Relative Volume:
0.99
時価総額：
$1.34B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.31%
1か月 パフォーマンス:
+21.40%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$21.51
$23.32
1週間の範囲:
$20.92
$23.32
52週間の値動き範囲:
$14.14
$24.99
Omada Health Inc Stock (OMDA) Company Profile
OMDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OMDA
Omada Health Inc
|
23.32 | 1.25B | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
293.59 | 46.82B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
73.23 | 13.26B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
67.99 | 12.56B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
87.98 | 7.72B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.17 | 6.47B | 906.14M | -52.62M | 89.62M | -0.3621 |
Omada Health Inc Stock (OMDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | 開始されました | Barclays | Overweight |
| 2025-07-01 | 開始されました | Canaccord Genuity | Buy |
| 2025-07-01 | 開始されました | Evercore ISI | Outperform |
| 2025-07-01 | 開始されました | Goldman | Buy |
| 2025-07-01 | 開始されました | JP Morgan | Overweight |
| 2025-07-01 | 開始されました | Morgan Stanley | Overweight |
| 2025-07-01 | 開始されました | Needham | Buy |
すべてを表示
Omada Health Inc (OMDA) 最新ニュース
Omada Health shares rise 3.31% intraday after announcing participation in Morgan Stanley's Global Healthcare Conference. - AInvest
Virtual Healthcare Leader Omada Health to Present at Morgan Stanley's 23rd Global Healthcare Conference - Stock Titan
Healthcare Analysts Bullish on CSL, UnitedHealth, and Omada Health - AInvest
Omada Health stock rises on market debut - MSN
U.S. Digital Therapeutics Market Positioned for Accelerated - openPR.com
Digital health Q2 earnings: New guys win, GLP-1 companies lose - Modern Healthcare
Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Gilead Sciences (GILD) and Cytokinetics (CYTK) - The Globe and Mail
Omada Health, Inc.: Strong Market Position and Growth Potential Justify Buy Rating - TipRanks
Omada grows revenue, membership in public earnings debut - Healthcare Dive
Omada Health 2025 Q2 Earnings Losses Narrow Sharply, 50% Year-Over-Year Reduction in Net Loss - AInvest
Omada Health revenue jumps 49% year-over-year post-IPO - TechTarget
Goldman Sachs raises Omada Health stock price target to $31 on strong Q2 By Investing.com - Investing.com South Africa
Goldman Sachs raises Omada Health stock price target to $31 on strong Q2 - Investing.com Nigeria
Barclays raises Omada Health PT to $24, maintains Overweight rating. - AInvest
Freedom Broker lowers Omada Health stock price target to $20 from $26 - Investing.com India
Freedom Broker lowers Omada Health stock price target to $20 from $26 By Investing.com - Investing.com South Africa
Omada Health price target raised to $28 from $27 at Canaccord - TipRanks
Omada Health price target raised to $24 from $21 at Barclays - TipRanks
Omada Health Reports Strong Q2 2025 Growth - TipRanks
Omada Health reports Q2 EPS (24c), consensus (13c) - TipRanks
Omada Health beats on revenue in first earnings report since IPO - CNBC
Omada Health Reports Second Quarter 2025 Results - The Manila Times
Earnings Flash (OMDA) Omada Health, Inc. Reports Q2 Revenue $61.4M, vs. FactSet Est of $55.3M - MarketScreener
U.S. Digital Therapeutics Market to Witness Remarkable Growth - openPR.com
Omada Health, Inc. (NASDAQ:OMDA) Receives $23.86 Average PT from Analysts - Defense World
Omada Health’s Strategic Partnerships and AI Leverage Drive Growth and Profitability Outlook - TipRanks
Health Coach Market is evolving rapidly Through 2025 To 2032 | Noom, Inc., HealthifyMe, Omada Health - openPR.com
Digital Therapeutics for Diabetes Market is projected to reach - openPR.com
Omada Health: Long Growth Runway Ahead - Seeking Alpha
Omada Health: A Buy Rating for a Company with Strong Distribution Partnerships and Clinical Validation - AInvest
Omada Health Sets Q2 Earnings Date: Virtual Healthcare Leader Reports August 7 - Stock Titan
Interleukin Inhibitors Market Generated Opportunities, Future Scope by 2032 | Noom, Inc., HealthifyMe, Omada Health - openPR.com
Omada Health, Inc.: A Promising Buy Amid Technical Weakness and Growth Potential - TipRanks
IPO market remains 'sluggish' despite recent San Francisco listings - The Business Journals
EQBK issues 1.73M shares, completes NBC merger & adds new director | OMDA SEC FilingForm 4 - Stock Titan
More than $16B in med-tech funding raised through 1H25 - BioWorld MedTech
The Making of Omada Health | Omada Health Co-Founder & CEO Sean Duffy - iHeart
These are the 9 healthcare startups next in line to go public, according to bankers and investors - Business Insider
Omada Health IPO signals healthier market, avoids ‘down-round’ trend - MSN
Health Coach Market Set to Witness Significant Growth by 2025-2032 | Noom, Inc., HealthifyMe, Omada Health - newstrail.com
Omada Health Stock (OMDA): A Growth Story in Digital Health - Value The Markets
Omada Health stock initiated with Buy rating at Freedom Broker - Investing.com
Needham initiates coverage on Omada Health stock with Buy rating By Investing.com - Investing.com India
Omada Health initiated with a Buy at Needham - TipRanks
Omada Health initiated with an Overweight at JPMorgan - TipRanks
Omada Health initiated with an Overweight at Morgan Stanley - TipRanks
Omada Health initiated with an Overweight at Barclays - TipRanks
Don’t expect a wave of digital health IPOs quite yet - Modern Healthcare
Omada Health initiated with a Buy at Goldman Sachs - TipRanks
Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential - TipRanks
Needham initiates coverage on Omada Health stock with Buy rating - Investing.com
Omada Health Inc (OMDA) 財務データ
Omada Health Inc (OMDA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.86%
0.17%
大文字化:
|
ボリューム (24 時間):